Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Receives $15.33 Average Price Target from Analysts

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have received a consensus rating of “Buy” from the five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $15.3333.

Several research firms have recently issued reports on RADX. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Thursday, January 22nd. B. Riley Financial restated a “buy” rating and set a $16.00 price target (up from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th. Finally, Wall Street Zen lowered Radiopharm Theranostics to a “strong sell” rating in a report on Friday, January 23rd.

Hedge Funds Weigh In On Radiopharm Theranostics

A number of hedge funds have recently made changes to their positions in RADX. PNC Financial Services Group Inc. lifted its holdings in shares of Radiopharm Theranostics by 100.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock worth $88,000 after acquiring an additional 8,000 shares during the period. Marex Group plc acquired a new position in Radiopharm Theranostics in the fourth quarter worth about $54,000. Jane Street Group LLC bought a new position in Radiopharm Theranostics during the fourth quarter worth about $76,000. Finally, Virtu Financial LLC acquired a new stake in Radiopharm Theranostics during the fourth quarter valued at approximately $76,000.

Radiopharm Theranostics Stock Up 1.8%

Shares of RADX stock opened at $5.05 on Wednesday. Radiopharm Theranostics has a 1 year low of $3.50 and a 1 year high of $16.25. The firm’s fifty day simple moving average is $5.08 and its 200 day simple moving average is $5.39.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.